Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial

@inproceedings{Jensterle2017ShorttermEO,
  title={Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial},
  author={Mojca Jensterle and Nika Aleksandra Kravos and Katja Gori{\vc}ar and Andrej Jane{\vz}},
  booktitle={BMC endocrine disorders},
  year={2017}
}
BackgroundLiraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it could enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCOS.MethodsThirty obese women with PCOS (aged 33.1 ± 6.1 years, BMI 38.3 ± 5.4 kg/m2) were randomized to combination (COMBO) of metformin (MET) 1000 mg BID and liraglutide 1.2 mg QD (N = 15) or… CONTINUE READING
BETA
4
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.

  • Biochemical and biophysical research communications
  • 2002
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.

  • Diabetic medicine : a journal of the British Diabetic Association
  • 2015
VIEW 1 EXCERPT

Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

T Vilsboll, M Christensen, AE Junker, FK Knop, LL. Gluud
  • BMJ. 2012;344:d7771
  • 2012
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…